Greenland Mines (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company’s Biotech Division. The patent protects the expression of the human Klotho protein for treating neuromuscular diseases, including constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems.
The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform, particularly its KLTO-202 program targeting amyotrophic lateral sclerosis (ALS) and other neuromuscular disorders. ALS is a progressive neurodegenerative disease affecting nerve cells in the brain and spinal cord, with limited treatment options. The Klotho protein has been studied for its potential neuroprotective and anti-aging effects, making it a promising target for gene therapy.
This development is significant for the biotech industry as it reinforces the company's commitment to advancing gene therapy solutions for debilitating diseases. For leaders in business and technology, the patent underscores the growing intersection of mining and biotech within the company's diversified portfolio. Greenland Mines operates two divisions: Mining, focused on the Skaergaard Project in Greenland and the Sarfartoq rare earths project, and Biotech, including the KLTO-202 program. The company's strategy is to build a multi-asset platform with exposure to rare earth magnet materials, precious metals, and midstream processing, while advancing its North Atlantic Critical Metals Corridor vision.
The patent grant could have broad implications for patients, healthcare systems, and investors. If KLTO-202 proves successful in clinical trials, it could offer a new therapeutic avenue for ALS patients, potentially slowing disease progression. For the industry, it validates the Klotho gene therapy approach, potentially attracting more research and investment into similar platforms. For investors, the strengthened IP portfolio may enhance the company's valuation and partnership opportunities.
Greenland Mines noted that the patent further supports development of its KLTO-202 program. The full press release is available at https://nnw.fm/PVbbH. Additional updates are available in the company’s newsroom at https://ibn.fm/GRML.
Forward-looking statements in the release are subject to risks and uncertainties as detailed in the company's SEC filings. This news matters because it highlights a strategic move by a Nasdaq-listed company to secure intellectual property in a high-impact area of gene therapy, potentially affecting the competitive landscape for ALS treatments and the broader biotech sector.
